Unveiling the Potential Drug Target TUBA1B: The tubulin Alpha- Ubiquitous Chain in Neurodegenerative Disorders

Target Name: TUBA1B

NCBI ID: G10376

TUBA1B

Unveiling the Potential Drug Target TUBA1B: The tubulin Alpha- Ubiquitous Chain in Neurodegenerative Disorders

Tubulin alpha-ubiquitous chain (TUBA1B) is a protein that plays a crucial role in the structure and function of microtubules, which are dynamic organelles that transport and support various cellular processes in eukaryotic cells. The TUBA1B protein is composed of several domains, including an alpha-tubulin protein, beta-tubulin protein, and a unique N-terminal region that contains a ubiquitin-like domain. This protein has been implicated in various neurodegenerative diseases, making it an attractive drug target or biomarker. In this article, we will discuss the TUBA1B protein, its functions, potential drug targets, and its potential as a biomarker for neurodegenerative diseases.

Structure and Function

Tubulin alpha-ubiquitous chain (TUBA1B) is a 25 kDa protein that contains four distinct domains: alpha-tubulin, beta-tubulin, N-terminal region, and a unique region that contains a ubiquitin-like domain. The alpha-tubulin and beta-tubulin domains form the core of the protein, while the N-terminal region interacts with various cellular structures, including the microtubule organizing matrix (MTOM) and the endoplasmic reticulum (ER).

The alpha-tubulin protein is composed of 185 amino acids and contains a 15.5 kDa alpha-helix, which is the region that gives the protein its unique structure and stability. The beta-tubulin protein is composed of 174 amino acids and contains a 13.2 kDa beta-helix, which is similar in structure to the alpha-tubulin protein. However, unlike the alpha-tubulin protein, the beta-tubulin protein is not as stable and is often used as a substitute for the alpha-tubulin protein in cell studies.

The N-terminal region of TUBA1B is 94 amino acids long and contains a unique protein that is involved in the interaction with various cellular structures, including the MTOM and ER. The N-terminal region contains a nucleotide-binding oligomerization domain (NBO domain), which is responsible for the interaction with the MTOM protein. In addition, the N-terminal region contains a carboxy-terminal domain (CTD), which is involved in the interaction with various cellular signaling pathways.

Potential Drug Targets

TUBA1B has been implicated in various neurodegenerative diseases, making it an attractive drug target or biomarker. One of the main reasons for this is the presence of misshapened microtubules, which are a hallmark of neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease, and Huntington's disease. In addition, the TUBA1B protein has been shown to play a role in the regulation of microtubule dynamics and stability, which may be involved in the pathophysiology of neurodegenerative diseases.

Several studies have identified potential drug targets for TUBA1B. For example, overexpression of the TUBA1B protein has been shown to reduce the formation of misshapened microtubules, which may be involved in the pathophysiology of neurodegenerative diseases. In addition, the TUBA1B protein has been shown to interact with various drugs, including taxanes, which are commonly used to treat

Protein Name: Tubulin Alpha 1b

Functions: Tubulin is the major constituent of microtubules, a cylinder consisting of laterally associated linear protofilaments composed of alpha- and beta-tubulin heterodimers (PubMed:34996871). Microtubules grow by the addition of GTP-tubulin dimers to the microtubule end, where a stabilizing cap forms (PubMed:34996871). Below the cap, tubulin dimers are in GDP-bound state, owing to GTPase activity of alpha-tubulin (PubMed:34996871)

The "TUBA1B Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TUBA1B comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets